

Estrogenic Control of Mitochondrial Function and Biogenesis

Carolyn M. Klinge*

Department of Biochemistry & Molecular Biology, Center for Genetics and Molecular Medicine, University of Louisville School of Medicine, Louisville, Kentucky 40292

ABSTRACT

Estrogens have cell-specific effects on a variety of physiological endpoints including regulation of mitochondrial biogenesis and activity. Estrogens regulate gene transcription by the classical genomic mechanism of binding to estrogen receptors α and β (ER α and ER β) as well as the more recently described nongenomic pathways involving plasma membrane-associated ERs that activate intracellular protein kinase-mediated phosphorylation signaling cascades. Here I will review the rapid and longer-term effects of estrogen on mitochondrial function. The identification of ER α and ER β within mitochondria of various cells and tissues is discussed with a model of estrogen regulation of the transcription of nuclear respiratory factor-1 (NRF-1, *NRF1*). NRF-1 subsequently promotes transcription of mitochondrial transcription factor Tfam (mtDNA maintenance factor, also called mtTFA) and then Tfam targets mtDNA-encoded genes. The nuclear effects of estrogens on gene expression directly controlling mitochondrial biogenesis, oxygen consumption, mtDNA transcription, and apoptosis are reviewed. Overall, we are just beginning to evaluate the many direct and indirect effects of estrogens on mitochondrial activities. *J. Cell. Biochem.* 105: 1342–1351, 2008. © 2008 Wiley-Liss, Inc.

KEY WORDS: ESTROGEN; ESTROGEN RECEPTOR; NRF-1; Tfam

Women have longer life expectancies in developed countries than men and this difference has been attributed to protective effects of premenopausal estrogens [Vina et al., 2005]. Mitochondrial reactive oxygen species (ROS) production during ATP generation by the electron transport chain (ETC) damages macromolecules including mitochondrial DNA (mtDNA). Damaged molecules and mitochondrial dysfunction accumulate over time and contribute to aging [Guarente, 2008]. Estrogens exert direct and indirect effects on mitochondrial function in a variety of tissues. While the neuroprotective effects of estrogen are arguably the best-studied, the mechanisms by which estrogens achieve their physiological and pharmacological effects are complex and not completely elucidated [reviewed in Simpkins et al., 2008]. Indeed, the impact of steroid hormones, including estradiol (E₂) on mitochondrial function “is a new and novel area of investigation” [Gavrilova-Jordan and Price, 2007]. The ability of estrogen to regulate nuclear DNA- and mitochondrial DNA (mtDNA)- encoded mitochondrial genes in MCF-7 cells was recently reviewed and the authors concluded that mitochondrial effects of estrogen may play a role in breast cancer, cardiovascular function, and gender-differences in neuroprotection [Gavrilova-Jordan and Price, 2007]. The role of estrogens in mitochondria and the role of mitochondria on nuclear estrogen action has been reviewed [Felty

and Roy, 2005a,b; Chen et al., 2008]. In breast cancer cells, Felty and Roy speculated that E₂ acts via membrane ER (mER) or mitochondrial ER (mtER) in breast cancer cell lines to alter three mitochondrial pathways: (1) direct interaction with the mitochondrial respiratory complexes (MRC) generates ROS leading to protein kinase activation; (2) mER activation of Ca⁺⁺-dependent proteases and protein kinases; and (3) mER activation causes cytoskeletal changes leading to mitochondrial changes and protein kinase activation [Felty and Roy, 2005a]. Whether this model differs in a cell-type-specific manner remains to be evaluated. Further, the role of estrogens in protecting against mitochondrial ROS damage associated with aging has been disputed based on study of C57Bl/6 mice in which males and females have similar longevity [Sanz et al., 2007]. This observation reflects the complexity of estrogen action at the molecular level.

Another topic of debate in understanding how estrogens affect mitochondrial function is whether there is a direct role for estrogen receptors α and β (ER α and ER β) localized within mitochondria on mtDNA gene transcription and mitochondrial function. A number of steroid/nuclear receptors (NR) in addition to ER α and ER β , that is, glucocorticoid receptor (GR), androgen receptor (AR), thyroid receptor (TR), retinoid X receptor (RXR), retinoic acid receptor (RAR), and peroxisome proliferator activated receptor gamma

Grant sponsor: NIH; Grant numbers: R01 DK53220, R21 CA124811.

*Correspondence to: Dr. Carolyn M. Klinge, Department of Biochemistry & Molecular Biology, Center for Genetics and Molecular Medicine, University of Louisville School of Medicine, Louisville, KY 40292.

E-mail: carolyn.klinge@louisville.edu

Received 27 August 2008; Accepted 29 August 2008 • DOI 10.1002/jcb.21936 • 2008 Wiley-Liss, Inc.

Published online 7 October 2008 in Wiley InterScience (www.interscience.wiley.com).

(PPAR γ 2), have been reported to be present in the mitochondria of various cell types and tissues [reviewed in Psarra and Sekeris, 2008]. However, there are those who dispute these findings. For example, Gustafsson's group reported that ER β could not be positively identified in mouse liver mitochondria by MALDI-TOF mass spectrometry [Schwend and Gustafsson, 2006]. This finding was refuted based on the fact that ER β expression is low in mouse liver and that the mitochondrial localization of ER may be cell-specific because ER β was identified in human heart mitochondrial proteins by MALDI-TOF [Yang et al., 2006].

We recently reported that E₂ increases the transcription and protein expression of nuclear respiratory factor-1 (NRF-1) and upregulates mitochondrial biogenesis in MCF-7 human breast cancer cells through activation of genomic ER α function [Mattingly et al., 2008]. NRF-1 is a key nuclear-encoded transcription factor that regulates the expression of a number nuclear-encoded genes regulating mitochondrial function [Scarpulla, 2006]. Interestingly, NRF-1 and many MRC genes were recently identified as E₂-regulated in opposite directions by ER α and ER β in mouse aorta [O'Lone et al., 2007]. Many questions regarding the mechanisms by which E₂ regulates mitochondrial function remain to be addressed [Burris and Krishnan, 2005]. This review will summarize the mechanisms of estrogen action, discuss transcriptional regulation of the mitochondrial genome, and provide an overview on various aspects of estrogen action in mitochondria. I apologize in advance for the many scientists/references that are not cited directly but whose work is included in reviews that are cited due to limitations of the format for this article.

GENOMIC ESTROGEN ACTION

The genomic activity of estrogens is mediated by ER α and ER β that are members of the steroid/nuclear receptor superfamily of transcription factors. The ER protein is divided into six domains: A–F [Kuiper et al., 1998]. The A/B N-terminal domain has low amino acid (aa) homology between ER α and ER β and regulates transcription by activating function 1 (AF-1) in a ligand-independent, cell-specific manner. In contrast, the DNA binding domain (DBD), domain C, has high aa homology between the two ER subtypes. The ligand binding domain (LBD) and AF-2 in the E and F domains share 59% and 18% aa homology, respectively [Kuiper et al., 1996]. Once activated by E₂, or an estrogen-like compound, ERs form homodimers or heterodimers of ER α /ER β and bind with high affinity to estrogen response elements (EREs) in the promoters, introns, or 3' untranslated regions of target genes [reviewed in Klinge, 2000]. The ERE is composed of a 15 bp palindromic inverted repeat consensus sequence: 5'-AGGTCAnnnTGACCT-3' (n = any nucleotide) [Klinge, 2003]. Figure 1 shows E₂-ER bound to an ERE within the nucleus. In addition to direct ERE binding, ER α and ER β interact with DNA-bound transcription factors, for example, Sp1 or AP1, at their binding sites and via a "tethering mechanism" activate transcription [reviewed in Klinge, 2000]. ER α and ER β interact with NF- κ B to inhibit transcription [Kalaitzidis and Gilmore, 2005]. Ligand-activated ERs mediate their genomic effects through interactions with coactivators that recruit chromatin remodeling




Fig. 1. ER α and ER β have genomic and nongenomic/membrane initiated activities. As reviewed in the text, ER α and ER β are located in the cytoplasm and nucleus, within caveolae in the plasma membrane and within mitochondria. For genomic (nuclear) ER activity, E₂ binds and activates ER causing dimerization, ERE binding (or interaction with other transcription factors bound to DNA, not shown), coactivator recruitment, chromatin remodeling, and increased transcription in the nucleus. For nongenomic/membrane initiated estrogen signaling, E₂ binds ER in caveolae in the plasma membrane. ER interacts with G-proteins, the p85 subunit of PI3K, with c-Src, and caveolin-1 (Cav-1) to initiate PI3K/AKT and MAPK signaling cascades. In the cytoplasm, ER interacts with MNAR and Shc which play a role in the nongenomic activities of ER. ER interacts with the EGF- and IGF-1 receptors in plasma membranes. ER in mitochondria interact with the D-loop of mtDNA and directly increase MnSOD activity.

complexes, alter nucleosomal structure, enhance recruitment of general transcription factors, and increase recruitment of RNA polymerase II to transcribe target genes [McKenna and O'Malley, 2002]. According to my count of the literature, 60 different protein coactivators have been reported to interact with ER α and/or ER β . The total number of NR coactivators is 200 [Lonard and O'Malley, 2006]. Coactivators exist in large complexes of proteins with many activities in addition to the initiation of transcription, including topoisomerase II [Ju et al., 2006], mRNA translation and splicing, and post-translational protein modifications [reviewed in Klinge, 2000]. When ER α is occupied by the selective ER modulator (SERM) 4-hydroxytamoxifen (4-OHT), the conformation of a critical α -helix (helix 12) within the LBD, is altered such that the coactivator binding groove is unavailable and corepressors, for example, silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) and nuclear receptor corepressor (NCoR), interact with the LBD and recruit histone deacetylase (HDAC) complexes to suppress gene transcription in a cell type- and gene-dependent manner [Smith and O'Malley, 2004]. The NURSA website has further information on coactivators, corepressors and chromatin remodeling at <http://www.nursa.org>.

In addition to regulation by ligand binding and coregulator protein recruitment, ERs are regulated by phosphorylation in both a

ligand-dependent [Lannigan, 2003] and ligand-independent manner [Feng et al., 2001]. Depending on which sites of ER α are phosphorylated, phosphorylation can either increase [Denton and Notides, 1992; Tzeng and Klinge, 1996; Coleman et al., 2003] or inhibit ER α -DNA binding [Al-Dhaheeri and Rowan, 2007] and alter nuclear localization [Picard et al., 2008], and thus alter gene transcription. MAPK phosphorylates the N-terminus of ER β , enhancing ER β -SRC-1-CBP interaction and gene transcription [Tremblay and Giguere, 2001]. E₂ binding promotes ER α ubiquitination and targeting to the 26S proteasome as a regulatory mechanism for ER turnover [Wijayaratne and McDonnell, 2001]. Likewise, ER β stability is also regulated by phosphorylation and ubiquitination [Picard et al., 2008]. Other post-translational modifications including glycosylation [Cheng and Hart, 2001; Li et al., 2003] and sumoylation also regulate ER α and ER β activity.

NONGENOMIC ESTROGEN ACTION

E₂ has “nongenomic, extra-nuclear, or membrane-initiated” effects, that is, independent of ER-mediated transcription, that occur within minutes after E₂ administration in a G-protein-coupled manner [as reviewed in Pedram et al., 2006a; Watson et al., 2007; Arpino et al., 2008]. Since ER α lacks a transmembrane domain, how it gets to the plasma membrane (PM) has been controversial but it appears to require palmitoylation [Moriarty et al., 2006]. ER α or its splice variant ER α 46 (N-terminally truncated so that the A/B domain and thus AF-1 is missing) also interacts with a number of proteins that are part of a “signalsome complex” including c-Src, the p85 subunit of PI3K, caveolin-1, straitin, MNAR (modulator of nongenomic activity of ER), and eNOS located in caveolae in the PM [Li et al., 2007]. ER α has been shown to interact with the EGF-receptor (EGFR), IGFR1, and HER2 in the plasma membrane of breast cancer cells [reviewed in Pietras and Marquez-Garban, 2007]. Figure 1 depicts an overview of nongenomic ER interactions. In MCF-7 cells, the adaptor protein Shc shuttles ER α from the nucleus to the PM where ER α interacts with the IGF-1 receptor (IGF-1R) [Song et al., 2004] and arginine methylation of ER α R260 by PRMT1 was recently shown to be essential for complex formation [Le Romancer et al., 2008]. In endothelial cells (EC), E₂ rapidly increased intracellular cAMP [Farhat et al., 1996], inhibited of Ca⁺² influx [Mueck et al., 1996], stimulated Ca⁺² release from internal stores [Improta-Brears et al., 1999], and stimulated nitric oxide (NO) production [Kausar and Rubanyi, 1997]. In MCF-7 human breast cancer cells, E₂ rapidly increased PIP2-phospholipase C activity [Graber et al., 1993], mobilized intracellular Ca²⁺, and activated the MAPK [Improta-Brears et al., 1999] and PI3K/AKT pathways [Stoica et al., 2003].

An “orphan” 7-transmembrane G protein-coupled receptor, GPR30, was reported to bind E₂ with high affinity (K_d = 2.7 nM) resulting in activation of adenylate cyclase, MAPK, AKT, and calcium signaling [reviewed in Prossnitz et al., 2008]. Interestingly, and in contrast to ER α or ER β , tamoxifen and ICI 182,780 (Fulvestrant) also bind GPR30 with high affinity and mimic the effects of E₂ [Thomas et al., 2005]. Although the role of GPR30 has been questioned [Pedram et al., 2006a; Otto et al., 2008], it appears likely that differences between cell/tissue types, for example,

thyroid [Vivacqua et al., 2006] or brain [Raz et al., 2008], may be responsible for whether GPR30 is a *bona fide* novel membrane estrogen receptor.

TRANSCRIPTIONAL REGULATION OF THE MITOCHONDRIAL GENOME

Essential metabolic pathways for energy production and homeostasis are located in mitochondria, for example, the MRC of oxidative phosphorylation for ATP production, heme biosynthesis, β -oxidation, metabolism of certain amino acids, and steroid synthesis. Mitochondrial DNA (mtDNA) is a 16.5 kb circular genome encoding 13 mRNAs, 2 rRNAs, and 22 tRNAs with 10³–10⁴ copies of mtDNA/mammalian cell [Chen et al., 2005]. Thirteen of the 80 proteins of the ETC complexes I, II, III, IV, and V are encoded by mtDNA [Chen et al., 2005]. The remaining subunits of the ETC as well as other proteins involved in mtDNA metabolism and function are nuclear-encoded [Chen et al., 2005]. Once translated, these proteins are targeted to mitochondria via a signal sequence and imported by translocases [Schmidt et al., 2001]. MtDNA transcription is initiated at two promoters (P_L and P_H) located in the D-loop regulatory region through the binding of mitochondrial RNA (mtRNA) polymerase and the mitochondrial transcription factors Tfam (mtDNA maintenance factor, also called mtTFA) and TFB (mitochondrial transcription factor B, *TFB1M* and *TFB2M*) [Scarpulla, 2006]. *TFAM*, *TFB1M*, and *TFB2M* are nuclear-encoded genes whose transcription is regulated by NRF-1 [Scarpulla, 2006]. Although mitochondrial gene expression depends on nuclear genome function and reciprocally by “retrograde communication” mitochondrial activity regulates nuclear gene expression [Poyton and McEwen, 1996], the mechanisms coordinating these events remain to be clarified.

ER α and ER β have been identified in mitochondria and to bind to the D-loop of mouse and human mtDNA [reviewed in Chen et al., 2008]. It is not clear whether ER α and ER β directly regulate mtDNA transcription or whether this effect is mediated through nuclear effects on nuclear-encoded genes that in turn regulate mtDNA transcription. Nonetheless, the presence of ER in both nucleus and mitochondria provide a possible mechanism for E₂ coordination of the expression of mtDNA and nuclear-encoded mitochondrial respiratory complex (MRC) genes. Whether ER is involved in retrograde communication between the mitochondria and nucleus is unknown. E₂ induces the transcription of nuclear-encoded MRC proteins including mitochondrial ATP synthase subunit E, COVII, and a number of other genes reviewed in [Chen et al., 2008].

NRF-1 IS A NUCLEAR TRANSCRIPTION FACTOR THAT REGULATES TRANSCRIPTION OF mtDNA TRANSCRIPTION FACTORS

NRF-1 is a 68 kDa protein containing an N-terminal nuclear localization signal and a C-terminal transcriptional activation domain that is ubiquitously expressed [Gugneja et al., 1996]. Homozygous deletion of murine NRF-1 results in embryonic death [Huo and Scarpulla, 2001]. NRF-1 homodimerizes and binds to

palindromic NRF-1 response elements (RE) in the promoter of nuclear-encoded mitochondrial genes, thus regulating the transcription of genes regulating mitochondrial activity in a cell-type specific manner [Scarpulla, 2002]. Research from Scarpulla's lab has demonstrated that NRF-1 plays a critical role in integrating nuclear-mitochondrial interactions by initiating transcription of nuclear-encoded mtDNA-specific transcription factors including Tfam, TFB1M, and TFB2M [Scarpulla, 2006]. Additional NRF-1 target genes include subunits of the five ETC complexes, components of the mtDNA transcription and replication machinery, mitochondrial and cytosolic enzymes of heme biosynthesis, components of mitochondrial protein import, and >400 genes involved in cell cycle regulation, metabolism, DNA replication, and transcriptional regulation [Cam et al., 2004]. Recently, NRF-1 was shown to bind and increase transcription of all 10 nuclear-encoded mouse *COX* genes [Dhar et al., 2008]. NRF-1 activity was inhibited by phosphorylation by cyclin D1 and NRF-1 interacts directly with cyclin D1 in MCF-7 cells [Wang et al., 2006]. The reciprocal regulation of cyclin D1 and NRF-1 was proposed to reduce mitochondrial activity and shift glucose metabolism toward glycolysis, that is, the Warburg effect, in cancer cells [Cuezva et al., 2002]. This hypothesis offers an explanation for the lack of inclusion of NRF1 in gene module analysis revealing an association of nuclear-encoded mitochondrial gene expression with reduced breast cancer survival [Wong et al., 2008]. This study reported increased expression of 218 nuclear-encoded mitochondrial genes including a number of NRF-1 targets, for example, *TFAM*, *SDHB*, and *COX5B*, although not NRF-1 itself, as associated with poor prognosis in breast cancer [Wong et al., 2008]. Notably, what regulates NRF-1 expression and activity is less well characterized [Scarpulla, 2006]. Thyroid hormone (T_3) increased NRF-1 transcription in rat liver "probably through a thyroid response element," although this element is undefined [Weitzel et al., 2001, 2003].

ESTROGEN REGULATES NRF-1 TRANSCRIPTION

Studies from Duckles' lab reported that NRF-1 was upregulated in the cerebral blood vessels of ovariectomized (ovex) rats chronically treated (2 weeks) with E_2 , suggesting that estrogen may regulate NRF-1 transcription [Stirone et al., 2005]. We followed up that observation at the molecular level and recently reported that NRF-1 mRNA expression was increased by E_2 in a time-dependent manner in two estrogen-responsive cell lines: MCF-7 breast cancer and H1793 lung adenocarcinoma cells [Mattingly et al., 2008]. The ER antagonist ICI 182,780 blocked the E_2 -induced increase in NRF-1 mRNA, indicating that ER mediates the E_2 -stimulated increase in NRF-1. The transcriptional inhibitor actinomycin D (Act D) and protein synthesis inhibitor cycloheximide (CHX) indicated that the E_2 -ER mediated increase in NRF-1 was a direct effect of ER at the genomic level. Indeed, pretreatment of MCF-7 cells for 1 h with the MAPK (MEK) and PI3K inhibitors PD98059 and Wortmannin, respectively, did not inhibit the E_2 -induced increase in NRF-1, indicating that the E_2 -induction of NRF-1 was not mediated by nongenomic/membrane-initiated activation of the PI3K/Akt and MAPK signaling pathways. We concluded that NRF-1 is a

primary E_2 -responsive gene [Mattingly et al., 2008]. NRF-1 protein expression increased in a time-dependent manner in E_2 -treated MCF-7 cells, commensurate with the increase seen in NRF-1 mRNA expression.

We reported that E_2 increased the interaction of both ER α and ER β with a 5' promoter region of the human NRF-1 gene containing an imperfect ERE [Mattingly et al., 2008]. However, siRNA against ER β did not inhibit E_2 -induced NRF-1 transcription, whereas siRNA against ER α did, thus implicating ER α as mediating the increase in NRF-1 induced by E_2 in MCF-7 cells. Thus, why E_2 increases ER β recruitment to the NRF1 promoter remains to be defined. However, recent microarray profiling of genes regulated by E_2 in aortas of wildtype, ER α , and ER β knockout (α ERKO and β ERKO) mice revealed opposite regulation of NRF-1 and many mitochondrial respiratory chain (MRC) gene targets by ER α and ER β [O'Lone et al., 2007]. Therefore, we hypothesize that the direct interaction of ER α and ER β with the NRF-1 promoter recruits different coregulators, that is, coactivators and corepressors, in a ligand- and cell-specific manner. Further, the regulation of NRF-1 transcription by estrogen may be cell type specific. Brown adipose tissue from male versus female Wistar rats showed higher transcript levels of *nrf1* and *tfam*, but not *pparg* [Rodriguez-Cuenca et al., 2007]. E_2 reduced *nrf1* and *tfam* transcription in primary cultured brown adipocytes from male NMRI mice [Rodriguez-Cuenca et al., 2007], the opposite of E_2 -induced *NRF1* in MCF-7 and H1793 cells [Mattingly et al., 2008]. A microarray gene profiling study showed a 7.3-fold increase in NRF-1 expression in Fulvestrant-resistant versus TAM-resistant MCF-7 cells [Table S2 in Fan et al., 2006], but no one has examined how TAM or 4-OHT affects *NRF1* expression in MCF-7 or other breast cancer cells.

ESTROGEN-INDUCED NRF-1 INCREASES Tfam AND Tfam INCREASES mtDNA GENE EXPRESSION

NRF-1 stimulates transcription of the Tfam gene by binding to an NRF-1 response element in the promoter [Scarpulla, 2006]. Subsequently, Tfam increases the transcription of mtDNA-encoded gene targets. We have reported that E_2 increased nuclear-encoded Tfam transcription in MCF-7 cells and also two mitochondrial-encoded mRNAs regulated by Tfam: Complex IV, cytochrome c oxidase subunit I; (*MTCO1*, COI) and NADH dehydrogenase subunit 1 (*MTND1*, ND1) [Mattingly et al., 2008]. Tfam mRNA was increased 12–72 h after E_2 treatment. The expression of Tfam-regulated, mtDNA-encoded *MTCO1* and *MTND1* mRNAs was increased 48–72 h after E_2 treatment and was inhibited by ICI 182,780, indicating an ER-dependence. COI and cytochrome c oxidase (COX IV, nuclear-encoded), both subunits of Complex IV in the MRC, protein expression was similarly increased by E_2 treatment [Mattingly et al., 2008]. *MTCO1* is transcriptionally regulated by Tfam and TFBs while COX IV is a direct target of NRF-1 [Scarpulla, 2006]. Thus, we proposed a model (Fig. 2) in which E_2 induced NRF-1 expression results in the increased expression of Tfam, as well as TFB1 and 2, and MRC genes, that subsequently entered mitochondria to increase the expression of mtDNA-encoded genes, mitochondrial biogenesis, and oxidative phosphorylation [Mattingly et al., 2008].




Fig. 2. E₂-ER α increases NRF-1 gene transcription. This model is based on our recent report showing that E₂-ER α binds a non-consensus ERE in the 5' promoter of the human NRF-1 gene and increases *NRF1* gene transcription [Mattingly et al., 2008]. The subsequent increase in NRF-1 protein increases the transcription of NRF-1 target genes in the nucleus, for example, increased *Tfam* transcription. PGC-1 α is a coactivator needed for NRF-1 regulated gene transcription. Increased *Tfam* as well MRC gene products are imported into mitochondria resulting in increased ETC oxidative phosphorylation. *Tfam* and TFB1 and TFB2 increase transcription of mtDNA and increase mitochondrial biogenesis.

EFFECT OF ESTROGENS ON MITOCHONDRIAL BIOGENESIS

Regulation of mitochondrial biogenesis involves the coordinated actions of both mtDNA and nuclear-encoded gene products including NRF-1, NRF-2, *Tfam*, and PGC-1 α [reviewed in Kelly and Scarpulla, 2004]. mtDNA copy number is a measure of mitochondrial biogenesis. Increased numbers of mitochondria and increased mitochondrial size were observed in the glandular epithelium and stromal endometrium of pregnant bonnet monkeys, an effect attributed to increased E₂ [Rosario et al., 2008]. We reported that E₂ significantly increased mtDNA copy number after 24, 48, and 72 h. in MCF-7 cells [Mattingly et al., 2008]. Because *Tfam* is essential for mtDNA replication [Larsson et al., 1998], these data are consistent with the increase in E₂-induced *Tfam* mRNA that we observed. Notably, siRNA knockdown of NRF-1 inhibited the E₂-induced increase in mtDNA, indicating that the E₂-induced increase in mitochondrial biogenesis is mediated by NRF-1 and not directly by E₂.

We note that the ability to estrogen to increase mitochondrial biogenesis may be cell-specific because E₂ treatment of ovariectomized (ovex) rats did not increase mitochondrial biogenesis as measured by the COXII (mitochondrial)/ β -actin (nuclear) ratio in brain [Irwin et al., 2008]. On the other hand, studies in male mouse heart following trauma-hemorrhage revealed that E₂ and the ER β agonist diarylpropionitrile (DPN) increased mitochondrial biogenesis via upregulation of mitochondrial ER β [Hsieh et al., 2006]. Further, mitochondrial ER β upregulated mtDNA transcription and MRC activity [Hsieh et al., 2006]. In mouse heart, E₂- or DPN-activated mitochondrial ER β specifically increased mitochondrial

respiratory complex-IV (MRC-IV, cytochrome c oxidase) activity [Hsieh et al., 2006]. E₂ also increased PGC-1 α mRNA and protein levels in the trauma-hemorrhage mouse heart model [Hsieh et al., 2005].

Isoflavones, for example, daidzen and genistein, are phytoestrogens that bind ER β and ER α with μ M affinities and have additional activities that are independent of ER binding [Kuiper et al., 1997]. Isoflavones were reported to increase mitochondrial biogenesis in primary rabbit renal proximal tubule cells (RPTC) in an ER-independent manner by increasing the expression and activity of sirtuin 1 (SIRT1) which in turn deacetylates and activates PGC-1 α [Rasbach and Schnellmann, 2008]. The coactivator PGC-1 α is considered a master regulator of mitochondrial biogenesis in mammals [reviewed in Ventura-Clapier et al., 2008]. On the other hand, genistein (0.5 μ M) was shown to decrease H₂O₂ levels in cells via nongenomic ER-activation of the MAPK pathway leading to NF κ B activation and increased MnSOD expression in MCF-7 cells [Borras et al., 2006]. Again, these results point to cell type-specific responses to phytoestrogens in affecting mitochondrial activities.

EFFECT OF ESTROGENS ON O₂ CONSUMPTION

There is surprisingly little information regarding the role of estrogen in regulating oxygen consumption as an index of MRC activity. An early study reported that E₂ inhibited oxygen consumption/mitochondrial respiration in isolated rat liver mitochondria with an IC₅₀ > 0.1 mM E₂ [Vallejos and Stoppani, 1967], a concentration which is not physiologically relevant since serum E₂ is 0.28 nM in follicular phase and 1.1 nM in luteal phase in premenopausal women [Clarke et al., 2003]. Rats in estrous had enhanced mitochondrial respiration compared to pseudopregnant or ovex rats, suggesting that E₂ increases mitochondrial respiration [Gigli and Bussmann, 2001]. Another study revealed that brain mitochondria isolated from E₂-treated ovex rats displayed significantly greater oxygen consumption following Ca⁺⁺ challenge in State 3 respiration and a significantly higher respiratory control ratio (RCR) than mitochondria from control rats [Nilsen et al., 2006]. We reported a significant increase in oxygen consumption after 4 and 6 days of E₂ treatment in MCF-7 cells [Mattingly et al., 2008]. This delayed time of response was consistent with the upregulation of COI and COIV proteins beginning at 48 h. Interestingly, E₂ did not increase oxygen consumption in MDA-MB-231 ER α -negative breast cancer cells [Mattingly et al., 2008].

DIRECT EFFECTS OF E₂, 4-OHT, AND RALOXIFENE WITHIN MITOCHONDRIA

Although μ M concentrations of E₂ have antioxidant activity in isolated hepatocytes [Leal et al., 1998], such levels are not physiologically relevant as indicated previously in this review. Likewise, although 4-hydroxytamoxifen was shown to specifically inhibit MRC Complexes III and IV (cytochrome c oxidase) in isolated rat liver mitochondria with IC₅₀s ~ 45–80 μ M [Tuquet et al., 2000], the serum concentration of 4-OHT in breast cancer patients on oral

tamoxifen is $\sim 0.2 \mu\text{M}$ [Clarke et al., 2003]. Numerous reports from Simpkins' lab have demonstrated the protective effects of E_2 against exogenous or endogenous ROS in neuronal and lens epithelial cells as measured by maintenance of ATP levels and inhibition of mitochondrial Ca^{++} influx [reviewed in Simpkins et al., 2008]. Studies from Yager's lab have demonstrated that E_2 increases superoxide production, O_2 uptake, and intracellular ATP levels through ER-activation because these effects are inhibited by Fulvestrant (ICI 182,780, a pure steroidal ER antagonist) [reviewed in Chen et al., 2008]. These data argue against any effect of the putative membrane estrogen receptor GPR30 since Fulvestrant activates GPR30 [reviewed in Filardo et al., 2006].

However, estrogen activation of membrane-associated ER (here referring to either $\text{ER}\alpha$ and/or $\text{ER}\beta$, i.e., the *ESR1* and *ESR2* gene products) thus initiating MAPK and NF- κB signaling resulting in increased transcription of mtDNA-encoded manganese-superoxide dismutase (MnSOD) and glutathione peroxidase (GPx) [Vina et al., 2005] offers a mechanism for estrogen's mitochondrial-protective activity. These enzymes detoxify ROS and thus protect mtDNA and macromolecules despite E_2 -activation of the MRC to increase ATP production and thus cell proliferation and movement [Chen et al., 2008]. However, this mechanism may be cell type-specific. In viral-transformed human lens epithelial cells (HLE-B3), E_2 rapidly activated MnSOD activity, but had no effect on MnSOD mRNA or protein expression [Gottipati and Cammarata, 2008]. In human brain microvascular endothelial cells (HBMECs), E_2 and Raloxifene (RAL) suppressed mitochondrial superoxide production through $\text{ER}\alpha$, not $\text{ER}\beta$, activation, but did not affect MnSOD RNA or protein levels in isolated mitochondria [Razmara et al., 2008]. E_2 increased the ratio of aconitase/fumarase enzyme activity, indicative of reduced ROS production in HBMECs. E_2 increased the transcription of cytochrome *c* through $\text{ER}\alpha$ activation in HBMECs and the authors suggested that the increase in cytochrome *c* by activating the cytochrome *c*-mediated electron-leak pathway, in which the electron of ferrocytochrome *c* migrates directly to H_2O_2 rather than to cytochrome *c* oxidase [Zhao and Xu, 2004], offers a mechanism by which E_2 suppresses ROS [Razmara et al., 2008]. Interestingly, NRF-1, which, as discussed previously, is directly upregulated by E_2 - $\text{ER}\alpha$ binding to an ERE in the *NRF1* promoter [Mattingly et al., 2008], directly regulates cytochrome *c* gene transcription by interacting with its palindromic response element in the promoter [Scarpulla, 2006], but whether the observed E_2 - $\text{ER}\alpha$ -induced increase in cytochrome *c* was mediated directly or through NRF-1 in HBMECs was not evaluated [Razmara et al., 2008].

E_2 directly increased MnSOD activity in isolated mitochondria from MCF-7 human breast cancer cells and thus reduced ROS [Pedram et al., 2006b]. The investigators in the Levin group also transfected ER-null CHO cells with a targeting vectors that specifically directed the expression of the E domain (ligand binding domain) of $\text{ER}\alpha$ to the plasma membrane, nucleus, or mitochondria and examined the effect of UV to increase apoptosis in the E_2 -treated cells [Pedram et al., 2006b]. Only the cells in which the $\text{ER}\alpha$ -E domain was targeted to mitochondria did E_2 prevent the UV-stimulated cytochrome *c* release [Pedram et al., 2006b], thus demonstrating the requirement of E_2 -E-domain interaction within mitochondria to inhibit apoptosis.

Physiological evidence for a role of $\text{ER}\alpha$ in mitochondrial function *in vivo* comes from studies with αERKO mice and ovex rodents. After subjecting αERKO versus wildtype(wt) mouse hearts to cardiac ischemia-reperfusion, mitochondria in the αERKO hearts showed ultrastructural damage and reduced ETC function [Zhai et al., 2000a]. In a similar study comparing myocardial ischemia-reperfusion injury in the hearts of ovex or E_2 -treated ovex rats, the E_2 -treated rats showed less myocardial mitochondrial damage and greater maintenance of ETC function [Zhai et al., 2000b]. Microarray profiling of aortas from ovex versus E_2 -supplemented ovex αERKO , βERKO , and wt mice identified >18 nuclear-encoded MRC subunits that are E_2 - $\text{ER}\alpha$ regulated [O'Lone et al., 2007]. Importantly, NRF-1 mRNA was decreased in the αERKO but not βERKO mice, indicating that E_2 - $\text{ER}\alpha$ regulates NRF-1 expression in mouse aorta. Notably, NRF-1 was downregulated by E_2 - $\text{ER}\beta$ and genes including an NRF-1-RE in the -1kB promoter were also downregulated in the aortas of αERKO mice indicating that $\text{ER}\beta$ actively represses a subset of MRC genes. A caveat of this study is that the mice were given 1 week of E_2 treatment [O'Lone et al., 2007]; thus, many identified genes are unlikely to be direct E_2 targets, but rather secondary or tertiary targets.

In vivo E_2 or progesterone treatment of ovex rats increased respiratory activity in isolated brain mitochondria [Irwin et al., 2008]. Both E_2 and progesterone also increased the mRNA levels of both nuclear and mtDNA-encoded components of the MRC, that is, mt-encoded COXI, COXII, and COXIII and nuclear encoded COXIV [Irwin et al., 2008]. Studies on changes in the proteome of mitochondria isolated from the brains of ovex rats treated for 24 h with E_2 revealed increased expression of many proteins that couple glucose utilization to the TCA cycle as well as ETC proteins, for example, complex IV subunits I-IV [Nilsen et al., 2007]. The authors concluded that E_2 regulates both mitochondrial and nuclear encoded genes, requiring coordinated control of mitochondrial and nuclear encoded gene transcription, a feat presumably regulated by the localization of ERs in both cellular organelles [Nilsen et al., 2007].

ER α AND ER β ARE INSIDE MITOCHONDRIA

Techniques including immunoblotting of mitochondrial preparations, immunocytochemistry, and mass spectrometry have revealed that $\text{ER}\beta$ is localized in mitochondria in a variety of tissues, including rabbit ovaries and uterus, human lens epithelial cells, spermatocytes, primary cerebral cortical and cerebral cortical and hippocampal neurons, primary cardiomyocytes, as well as HepG2, SaOS-2, and MCF-7 cell lines [reviewed in Psarra and Sekeris, 2008]. $\text{ER}\alpha$ has also been reported to be in mitochondria of a few tissues, for example, rabbit uterus [Monje and Boland, 2001] and in MCF-7 cells [reviewed in Chen et al., 2008], but many more cell lines have mitochondrial $\text{ER}\beta$ [reviewed in Psarra and Sekeris, 2008]. E_2 enhanced $\text{ER}\alpha$ and $\text{ER}\beta$ mitochondrial localization in MCF-7 cells [reviewed in Chen et al., 2008]. Other nuclear transcription factors, for example, p53, NF- κB , AP-1, CREB, wnt, c-src, and c-myc, have also been observed in mitochondria [reviewed in Psarra and Sekeris, 2008]. This raises the possibility that ER interaction with these proteins in the mitochondria may impact mtDNA gene expression or

other functions. On the other hand, a recent proteomic/bioinformatic analysis of mitochondrial proteins in 14 different C57Bl/6 mouse tissues did not reveal either ER α or ER β in any tissue, even with an estimated 85% of proteins identified and a false discovery rate of 10% [Pagliarini et al., 2008], see also <http://www.broad.mit.edu/publications/MitoCarta/>.

ER is transcriptionally active within mitochondria. An E₂-stimulated increase in mRNA levels of mtDNA-encoded genes cytochrome c oxidase subunits I and II (COI and COII) was inhibited by ICI 182,780, indicating ER-dependence [Chen et al., 2004a]. Yager's group identified a mitochondrial targeting protein sequence (mTPS) in ER β aa 220–270 and reported that ER α lacks a mTPS [Chen et al., 2004a]. Other studies indicate that ER β interaction with Tom70 and Hsp70 may play a role in mitochondrial trafficking of ER β [reviewed in Simpkins et al., 2008]. The D-loop of mtDNA contains replication and transcriptional control elements. ER β bound to D-loop EREs in MCF-7 mtDNA in vitro [Chen et al., 2004b]. Recently, ER β was reported to be predominantly localized in mitochondria of immortalized "normal" and E₂-transformed human breast epithelial cell lines (MCF-10F) [Chen et al., 2007]. Further, the Russo group reported that ER β shifts from mitochondria to nuclei during E₂-induced neoplastic transformation and that E₂ and the ER β -selective agonist DPN, but not the ER α -selective agonist PPT, induced expression of mtDNA-encoded MRC genes and proteins COI, COII, and ND1 [Chen et al., 2007]. However, the authors did not state how long the cells were treated with E₂ or DPN and thus whether the effect is primary or secondary, that is, due to increased NRF-1, Tfam, TFB1, etc. (as in Fig. 1), is unknown.

ESTROGENS INHIBIT APOPTOSIS

Programmed cell death, that is, apoptosis, is an energy-dependent series of cellular events that is critical in tissue remodeling during development, for example, the breast at puberty, during pregnancy/lactation, and involution, and is involved in breast cancer development [Conner, 2007]. Apoptosis can be initiated through either the intrinsic or extrinsic pathway leading to caspase activation [Kaufmann and Hengartner, 2001]. Mitochondria are central to the induction of apoptosis [van Heerde et al., 2000]. Growth factors and trophic hormones reciprocally regulate breast cell apoptosis and proliferation. In the pre-ovulatory phase of the menstrual cycle, when estrogen levels are high, breast cell apoptotic activity is low [Conner, 2007]. The intrinsic, mitochondrial-mediated apoptotic pathway is regulated by Bcl-2 family members that either promote or inhibit apoptosis depending on their interaction with pro-survival family members, for example, Bcl-2, Bcl-xL and Mcl-1, or pro-apoptotic, for example, Bax, Bak, and Bok, Bim, Bid, Puma, and Bad [Labi et al., 2008]. E₂ protects MCF-7 cells from apoptosis by upregulating transcription of anti-apoptotic/pro-survival Bcl-2 [Perillo et al., 2000]. In neuronal tissues, E₂ inhibits apoptosis by increasing mitochondrial sequestration of Ca⁺⁺ [Nilsen and Brinton, 2003; Nilsen and Brinton, 2004] and by suppressing transcription of pro-apoptotic genes such as *nip2* [Belcredito et al., 2000]. In addition, membrane-initiated E₂

activation of MAPK and PI3K/pathways is anti-apoptotic [Razandi et al., 2000].

Recent studies have identified microRNAs with anti- or pro-apoptotic functions [reviewed in Park and Peter, 2008]. Among the miRNA genes identified was let-7c that increased TRAIL-induced caspase 3 activation in MDA-MB-453 breast cancer cells, presumably by targeting CD95L [Ovcharenko et al., 2007]. Of interest in terms of estrogen regulation of apoptosis is the report that let-7c expression was higher in ER α positive than ER α negative human breast tumors [Blenkiron et al., 2007]. On the other hand, transfection of miR-182 inhibited TRAIL-induced caspase 3 activation in MDA-MB-453 breast cancer cells, presumably by targeting caspase 3 and Fas-associated death domain (FADD) protein [Ovcharenko et al., 2007]. Like let-7c, miR-182 was higher in ER α positive than ER α negative human breast tumors [Mattie et al., 2006]. We found that MCF-7 cells treated with 10 nM E₂ for 6 h increased miR-182 (the mature form of this miRNA) by ~3-fold as measured by realtime Q-PCR (Klinge, unpublished data). These data are consistent with a potential estrogen-mediated anti-apoptotic function of miR-182. However, remarkably little is known about estrogen regulation of miRNA expression, let alone the targets of miRNA in apoptosis.

Given that E₂ increases anti-apoptotic Bcl-2 and mtDNA-encoded MRC expression, and our report that E₂ increases NRF-1 [Mattingly et al., 2008], we propose that NRF-1 is also anti-apoptotic. Supporting this idea, knockout of NRF-1 regulated gene *Tfam* in mouse heart tissue, which results in deficiency in mtDNA transcription, was associated with increased in vivo apoptosis [Wang et al., 2001]. Indeed, one review concluded that the persistent E₂/ER-induced ETC protein synthesis and energy metabolism play an important role in apoptotic inhibition [Chen et al., 2005]. Additionally, cellular quiescence has been shown to be maintained by a balance between c-Myc and NRF-1 expression and the overexpression of c-Myc in cancer results in sensitization of cells to apoptosis under serum deprivation by selectively competing with NRF-1 for select NRF-1-target genes triggering apoptosis [Morrish et al., 2003]. Thus, another possible mechanism by which E₂ inhibits apoptosis is by increasing NRF-1 expression to achieve a higher ratio of NRF-1/c-Myc.

CONCLUSIONS

Estrogens have direct and indirect effects on mitochondrial activity that are mediated by genomic and nongenomic/membrane-initiated activities of ER α and ER β [reviewed in Felty and Roy, 2005a,b; Chen et al., 2008]. E₂ increases NRF-1 gene transcription by increasing ER α binding to an ERE in the gene promoter [Mattingly et al., 2008]. An increase in Tfam followed the E₂-induced increase in NRF-1 which was followed in time by increased Tfam-regulated mtDNA-encoded COI and NDI genes and increased mitochondrial biogenesis (modeled in Fig. 2). The localization of ER α and ER β in both nuclear and mitochondrial compartments offers a potential mechanism for regulating coordinate nuclear and mitochondrial gene expression and function that remains to be clarified.

ACKNOWLEDGMENTS

Sincere thanks to Dr. Barbara J. Clark for her thoughtful comments and suggestions for the improvement of this review.

REFERENCES

- Al-Dhaheri MH, Rowan BG. 2007. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor $\{\alpha\}$ promoter interaction, and changes in receptor phosphorylation. *Mol Endocrinol* 21:439–456.
- Arpino G, Wiechmann L, Osborne CK, Schiff R. 2008. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance. *Endocr Rev* 29:217–233.
- Belcredito S, Brusadelli A, Maggi A. 2000. Estrogens, apoptosis and cells of neural origin. *J Neurocytol* 29:359–365.
- Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavare S, Caldas C, Miska EA. 2007. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. *Genome Biol* 8:R214.
- Borras C, Gambini J, Gomez-Cabrera MC, Sastre J, Pallardo FV, Mann GE, Vina J. 2006. Genistein, a soy isoflavone, up-regulates expression of anti-oxidant genes: Involvement of estrogen receptors, ERK1/2, and NF $\{\kappa\}$ B. *FASEB J* 20:2136–2138.
- Burris TP, Krishnan V. 2005. Estrogen: A mitochondrial energizer that keeps on going. *Mol Pharmacol* 68:956–958.
- Cam H, Balciunaite E, Blais A, Spektor A, Scarpulla RC, Young R, Kluger Y, Dynlacht BD. 2004. A common set of gene regulatory networks links metabolism and growth inhibition. *Mol Cell* 16:399–411.
- Chen JQ, Delannoy M, Cooke C, Yager JD. 2004a. Mitochondrial localization of ER α and ER β in human MCF7 cells. *Am J Physiol Endocrinol Metab* 286:E1011–E1022.
- Chen JQ, Eshete M, Alworth WL, Yager JD. 2004b. Binding of MCF-7 cell mitochondrial proteins and recombinant human estrogen receptors α and β to human mitochondrial DNA estrogen response elements. *J Cell Biochem* 93:358.
- Chen J-Q, Yager JD, Russo J. 2005. Regulation of mitochondrial respiratory chain structure and function by estrogens/estrogen receptors and potential physiological/pathophysiological implications. *Biochim Biophys Acta (BBA): Mol Cell Res* 1746:1–17.
- Chen J-Q, Russo PA, Cooke C, Russo IH, Russo J. 2007. ER β shifts from mitochondria to nucleus during estrogen-induced neoplastic transformation of human breast epithelial cells and is involved in estrogen-induced synthesis of mitochondrial respiratory chain proteins. *Biochim Biophys Acta (BBA): Mol Cell Res* 1773:1732–1746.
- Chen JQ, Brown TR, Yager JD. 2008. Mechanisms of hormone carcinogenesis: Evolution of views, role of mitochondria. *Adv Exp Med Biol* 630:1–18.
- Cheng X, Hart GW. 2001. Alternative O-glycosylation/O-phosphorylation of serine-16 in murine estrogen receptor β : Post-translational regulation of turnover and transactivation activity. *J Biol Chem* 276:10570–10575.
- Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA. 2003. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. *Oncogene* 22:7316–7339.
- Coleman KM, Dutertre M, El-Gharbawy A, Rowan BG, Weigel NL, Smith CL. 2003. Mechanistic differences in the activation of estrogen receptor- α (ER α)- and ER β -dependent gene expression by cAMP signaling pathway(s). *J Biol Chem* 278:12834–12845.
- Conner P. 2007. Breast response to menopausal hormone therapy—Aspects on proliferation, apoptosis and mammographic density. *Ann Med* 39:28–41.
- Cuevas JM, Krajewska M, De Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M, Reed JC. 2002. The bioenergetic signature of cancer: A marker of tumor progression. *Cancer Res* 62:6674–6681.
- Denton RR, Notides AC. 1992. Estrogen receptor phosphorylation. Hormonal dependence and consequence on specific DNA binding. *J Biol Chem* 267:7263–7268.
- Dhar SS, Ongwijitwat S, Wong-Riley MTT. 2008. Nuclear respiratory factor 1 regulates all ten nuclear-encoded subunits of cytochrome c oxidase in neurons. *J Biol Chem* 283:3120–3129.
- Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng ASL, Li L, Abbosh PH, Huang THM, Nephew KP. 2006. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. *Cancer Res* 66:11954–11966.
- Farhat MY, Lavigne MC, Ramwell PW. 1996. The vascular protective effects of estrogen. *FASEB J* 10:615–624.
- Felty Q, Roy D. 2005a. Estrogen, mitochondria, and growth of cancer and non-cancer cells. *J Carcinog* 4:1.
- Felty Q, Roy D. 2005b. Mitochondrial signals to nucleus regulate estrogen-induced cell growth. *Med Hypotheses* 64:133–141.
- Feng W, Webb P, Nguyen P, Liu X, Li J, Karin M, Kushner PJ. 2001. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-Independent pathway. *Mol Endocrinol* 15:32–45.
- Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E. 2006. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. *Clin Cancer Res* 12:6359–6366.
- Gavrilova-Jordan LP, Price TM. 2007. Actions of steroids in mitochondria. *Semin Reprod Med* 25:154–164.
- Gigli I, Bussmann LE. 2001. Exercise and ovarian steroid hormones: Their effects on mitochondrial respiration. *Life Sci* 68:1505–1514.
- Gottipati S, Cammarata PR. 2008. Mitochondrial superoxide dismutase activation with 17 beta-estradiol-treated human lens epithelial cells. *Mol Vis* 14:898–905.
- Graber R, Sumida C, Vallette G, Nunez EA. 1993. Rapid and long-term effects of 17 beta-estradiol on PIP2-phospholipase C-specific activity of MCF-7 cells. *Cell Signal* 5:181–186.
- Guarente L. 2008. Mitochondria—A nexus for aging, calorie restriction, and sirtuins? *Cell* 132:171–176.
- Gugneja S, Virbasius CM, Scarpulla RC. 1996. Nuclear respiratory factors 1 and 2 utilize similar glutamine-containing clusters of hydrophobic residues to activate transcription. *Mol Cell Biol* 16:5708–5716.
- Hsieh Y-C, Yang S, Choudhry MA, Yu H-P, Rue LW III, Bland KI, Chaudry IH. 2005. PGC-1 upregulation via estrogen receptors: A common mechanism of salutary effects of estrogen and flutamide on heart function after trauma-hemorrhage. *Am J Physiol Heart Circ Physiol* 289:H2665–H2672.
- Hsieh Y-C, Yu H-P, Suzuki T, Choudhry MA, Schwacha MG, Bland KI, Chaudry IH. 2006. Upregulation of mitochondrial respiratory complex IV by estrogen receptor- β is critical for inhibiting mitochondrial apoptotic signaling and restoring cardiac functions following trauma-hemorrhage. *J Mol Cell Cardiol* 41:511–521.
- Huo L, Scarpulla RC. 2001. Mitochondrial DNA instability and peri-implantation lethality associated with targeted disruption of nuclear respiratory factor 1 in mice. *Mol Cell Biol* 21:644–654.

- Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP. 1999. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. *Proc Natl Acad Sci USA* 96:4686–4691.
- Irwin RW, Yao J, Hamilton RT, Cadenas E, Brinton RD, Nilsen J. 2008. Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. *Endocrinology* 149:3167–3175.
- Ju B-G, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld MG. 2006. A topoisomerase II{beta}-mediated dsDNA break required for regulated transcription. *Science* 312:1798–1802.
- Kalaitzidis D, Gilmore TD. 2005. Transcription factor cross-talk: The estrogen receptor and NF-[kappa]B. *Trends Endocrinol Metab* 16:46–52.
- Kaufmann SH, Hengartner MO. 2001. Programmed cell death: Alive and well in the new millennium. *Trends Cell Biol* 11:526–534.
- Kausar K, Rubanyi GM. 1997. Potential cellular signaling mechanisms mediating upregulation of endothelial nitric oxide production by estrogen. *J Vasc Res* 34:229–236.
- Kelly DP, Scarpulla RC. 2004. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. *Genes Dev* 18:357–368.
- Klinge CM. 2000. Estrogen receptor interaction with co-activators and co-repressors. *Steroids* 65:227–251.
- Klinge CM. 2003. Estrogen response element sequence as an allosteric regulator of estrogen receptor action. *ChemTracts Biochem Mol Biol* 16:1–18.
- Kuiper GG, Enmark E, Peltö-Huikko M, Nilsson S, Gustafsson J-A. 1996. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. *Proc Natl Acad Sci USA* 93:5925–5930.
- Kuiper GG, Carlsson B, Grandien J, Enmark E, Haggblad J, Nilsson S, Gustafsson J-A. 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β . *Endocrinology* 138:863–870.
- Kuiper GG, Shughrue PJ, Merchenthaler I, Gustafsson JA. 1998. The estrogen receptor β subtype: A novel mediator of estrogen action in neuroendocrine systems. *Front Neuroendocrinol* 19:253–286.
- Labi V, Grespi F, Baumgartner F, Villunger A. 2008. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: A breakthrough in anticancer therapy? *Cell Death Differ* 15:977–987.
- Lannigan DA. 2003. Estrogen receptor phosphorylation. *Steroids* 68:1–9.
- Larsson NG, Wang J, Wilhelmsson H, Oldfors A, Rustin P, Lewandoski M, Barsh GS, Clayton DA. 1998. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. *Nat Genet* 18:231–236.
- Le Romancer M, Treilleux I, Leconte N, Robin-Lespinasse Y, Sentis S, Bouchekioua-Bouzaghrou K, Goddard S, Gobert-Gosse S, Corbo L. 2008. Regulation of estrogen rapid signaling through arginine methylation by PRMT1. *Mol Cell* 31:212–221.
- Leal AM, Ruiz-Larrea MB, Martinez R, Lacort M. 1998. Cytoprotective actions of estrogens against tert-butyl hydroperoxide-induced toxicity in hepatocytes. *Biochem Pharmacol* 56:1463–1469.
- Li L, Haynes MP, Bender JR. 2003. Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells. *Proc Natl Acad Sci USA* 100:4807–4812.
- Li L, Hisamoto K, Kim KH, Haynes MP, Bauer PM, Sanjay A, Collinge M, Baron R, Sessa WC, Bender JR. 2007. Variant estrogen receptor c-Src molecular interdependence and c-Src structural requirements for endothelial NO synthase activation. *Proc Natl Acad Sci* 104:16468–16473.
- Lonard DM, O'Malley BW. 2006. The expanding cosmos of nuclear receptor coactivators. *Cell* 125:411–414.
- Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. 2006. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. *Mol Cancer* 5:24.
- Mattingly KA, Ivanova MM, Riggs KA, Wickramasinghe NS, Barch MJ, Klinge CM. 2008. Estradiol stimulates transcription of nuclear respiratory factor-1 and increases mitochondrial biogenesis. *Mol Endocrinol* 22:609–622.
- McKenna NJ, O'Malley BW. 2002. Combinatorial control of gene expression by nuclear receptors and coregulators. *Cell* 108:465–474.
- Monje P, Boland R. 2001. Subcellular distribution of native estrogen receptor α and β isoforms in rabbit uterus and ovary. *J Cell Biochem* 82:467–479.
- Moriarty K, Kim KH, Bender JR. 2006. Estrogen receptor-mediated rapid signaling. *Endocrinology* 147:5557–5563.
- Morrish F, Giedt C, Hockenbery D. 2003. c-MYC apoptotic function is mediated by NRF-1 target genes. *Genes Dev* 17:240–255.
- Mueck AO, Seeger H, Lippert TH. 1996. Calcium antagonistic effect of natural and synthetic estrogens—Investigations on a nongenomic mechanism of direct vascular action. *Int J Clin Pharmacol Ther* 34:424–426.
- Nilsen J, Brinton RD. 2003. Mechanism of estrogen-mediated neuroprotection: Regulation of mitochondrial calcium and Bcl-2 expression. *Proc Natl Acad Sci USA* 100:2842–2847.
- Nilsen J, Brinton RD. 2004. Mitochondria as therapeutic targets of estrogen action in the central nervous system. *Curr Drug Targets CNS Neurol Disord* 3:297–313.
- Nilsen J, Chen S, Irwin RW, Iwamoto S, Brinton RD. 2006. Estrogen protects neuronal cells from amyloid β -induced apoptosis via regulation of mitochondrial proteins and function. *BMC Neurosci* 7:74.
- Nilsen J, Irwin RW, Gallaher TK, Brinton RD. 2007. Estradiol in vivo regulation of brain mitochondrial proteome. *J Neurosci* 27:14069–14077.
- O'Lone R, Knorr K, Jaffe IZ, Schaffer ME, Martini PGV, Karas RH, Bienkowska J, Mendelsohn ME, Hansen U. 2007. Estrogen receptors { α } and { β } mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. *Mol Endocrinol* 21:1281–1296.
- Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, Langer G, Bader B, Prella K, Nubbemeyer R, Fritzscheimer K-H. 2008. GPR30 localizes to the endoplasmic reticulum and is not activated by estradiol. *Endocrinology* DOI: 10.1210/en.2008-0269.
- Ovcharenko D, Kelnar K, Johnson C, Leng N, Brown D. 2007. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. *Cancer Res* 67:10782–10788.
- Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, Walford GA, Sugiana C, Boneh A, Chen WK, Hill DE, Vidal M, Evans JG, Thorburn DR, Carr SA, Mootha VK. 2008. A mitochondrial protein compendium elucidates complex I disease biology. *Cell* 134:112–123.
- Park S-M, Peter ME. 2008. microRNAs and death receptors. *Cytokine Growth Factor Rev* 19:303–311.
- Pedram A, Razandi M, Levin ER. 2006a. Nature of functional estrogen receptors at the plasma membrane. *Mol Endocrinol* 20:1996–2009.
- Pedram A, Razandi M, Wallace DC, Levin ER. 2006b. Functional estrogen receptors in the mitochondria of breast cancer cells. *Mol Biol Cell* 17:2125–2137.
- Perillo B, Sasso A, Abbondanza C, Palumbo G. 2000. 17 β -estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. *Mol Cell Biol* 20:2890–2901.
- Picard N, Charbonneau C, Sanchez M, Licznar A, Busson M, Lazennec G, Tremblay A. 2008. Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor { β }. *Mol Endocrinol* 22:317–330.

- Pietras RJ, Marquez-Garban DC. 2007. Membrane-associated estrogen receptor signaling pathways in human cancers. *Clin Cancer Res* 13:4672–4676.
- Poyton RO, McEwen JE. 1996. Crosstalk between nuclear and mitochondrial genomes. *Annu Rev Biochem* 65:563–607.
- Prossnitz ER, Oprea TI, Sklar LA, Arterburn JB. 2008. The ins and outs of GPR30: A transmembrane estrogen receptor. *J Steroid Biochem Mol Biol* 109:350–353.
- Psarra AM, Sekeris CE. 2008. Steroid and thyroid hormone receptors in mitochondria. *IUBMB Life* 60:210–223.
- Rasbach KA, Schnellmann RG. 2008. Isoflavones promote mitochondrial biogenesis. *J Pharmacol Exp Ther* 325:536–543.
- Raz L, Khan MM, Mahesh VB, Vadlamudi RK, Brann DW. 2008. Rapid estrogen signaling in the brain. *Neurosignals* 16:140–153.
- Razandi M, Pedram A, Levin ER. 2000. Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. *Mol Endocrinol* 14:1434–1447.
- Razmara A, Sunday L, Stirone C, Wang XB, Krause DN, Duckles SP, Procaccio V. 2008. Mitochondrial effects of estrogen are mediated by estrogen receptor {alpha} in brain endothelial cells. *J Pharmacol Exp Ther* 325:782–790.
- Rodriguez-Cuenca S, Monjo M, Gianotti M, Proenza AM, Roca P. 2007. Expression of mitochondrial biogenesis-signaling factors in brown adipocytes is influenced specifically by 17beta-estradiol, testosterone, and progesterone. *Am J Physiol Endocrinol Metab* 292:E340–E346.
- Rosario GX, D'Souza SJ, Manjramkar DD, Parmar V, Puri CP, Sachdeva G. 2008. Endometrial modifications during early pregnancy in bonnet monkeys (*Macaca radiata*). *Reprod Fertil Dev* 20:281–294.
- Sanz A, Hiona A, Kujoth GC, Seo AY, Hofer T, Kouwenhoven E, Kalani R, Prolla TA, Barja G, Leeuwenburgh C. 2007. Evaluation of sex differences on mitochondrial bioenergetics and apoptosis in mice. *Exp Gerontol* 42:173–182.
- Scarpulla RC. 2002. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. *Biochim Biophys Acta (BBA): Gene Struct Expr* 1576:1–14.
- Scarpulla RC. 2006. Nuclear control of respiratory gene expression in mammalian cells. *J Cell Biochem* 97:673–683.
- Schmidt S, Strub A, Voos W. 2001. Protein translocation into mitochondria. *Biol Signals Recept* 10:14–25.
- Schwend T, Gustafsson J-A. 2006. False positives in MALDI-TOF detection of ER[beta] in mitochondria. *Biochem Biophys Res Commun* 343:707–711.
- Simpkins JW, Yang S-H, Sarkar SN, Pearce V. 2008. Estrogen actions on mitochondria—Physiological and pathological implications. *Mol Cell Endocrinol* 290:51–59.
- Smith CL, O'Malley BW. 2004. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. *Endocr Rev* 25:45–71.
- Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ. 2004. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor {alpha} to the plasma membrane. *Proc Natl Acad Sci* 101:2076–2081.
- Stirone C, Duckles SP, Krause DN, Procaccio V. 2005. Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. *Mol Pharmacol* 7:7.
- Stoica GE, Franke TF, Wellstein A, Czubyko F, List HJ, Reiter R, Morgan E, Martin MB, Stoica A. 2003. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. *Mol Endocrinol* 17:818–830.
- Thomas P, Pang Y, Filardo EJ, Dong J. 2005. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. *Endocrinology* 146:624–632.
- Tremblay A, Giguere V. 2001. Contribution of steroid receptor coactivator-1 and CREB binding protein in ligand-independent activity of estrogen receptor beta. *J Steroid Biochem Mol Biol* 77:19–27.
- Tuquet C, Dupont J, Mesneau A, Roussaux J. 2000. Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria. *Cell Biol Toxicol* 16:207–219.
- Tzeng DZ, Klinge CM. 1996. Phosphorylation of purified estradiol-liganded estrogen receptor by casein kinase II increases estrogen response element binding but does not alter ligand stability. *Biochem Biophys Res Commun* 223:554–560.
- Vallejos RH, Stoppani AO. 1967. Site-specific effects of steroids on mitochondrial metabolism. *Biochim Biophys Acta* 131:295–309.
- van Heerde WL, Robert-Offerman S, Dumont E, Hofstra L, Doevendans PA, Smits JF, Daemen MJ, Reutelingsperger CP. 2000. Markers of apoptosis in cardiovascular tissues: Focus on Annexin V. *Cardiovasc Res* 45:549–559.
- Ventura-Clapier R, Garnier A, Veksler V. 2008. Transcriptional control of mitochondrial biogenesis: The central role of PGC-1{alpha}. *Cardiovasc Res* 79:208–217.
- Vina J, Borrás C, Gambini J, Sastre J, Pallardo FV. 2005. Why females live longer than males? Importance of the upregulation of longevity-associated genes by oestrogenic compounds. *FEBS Lett* 579:2541–2545.
- Vivacqua A, Bonfigliolo D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Ando S, Maggiolini M. 2006. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30. *Mol Pharmacol* 70:1414–1423.
- Wang J, Silva JP, Gustafsson CM, Rustin P, Larsson N-G. 2001. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. *Proc Natl Acad Sci* 98:4038–4043.
- Wang C, Li Z, Lu Y, Du R, Katiyar S, Yang J, Fu M, Leader JE, Quong A, Novikoff PM, Pestell RG. 2006. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. *Proc Natl Acad Sci* 103:11567–11572.
- Watson CS, Aleya RA, Jeng YJ, Kochukov MY. 2007. Nongenomic actions of low concentration estrogens and xenoestrogens on multiple tissues. *Mol Cell Endocrinol* 274:1–7.
- Weitzel JM, Radtke C, Seitz HJ. 2001. Two thyroid hormone-mediated gene expression patterns in vivo identified by cDNA expression arrays in rat. *Nucl Acids Res* 29:5148–5155.
- Weitzel JM, Iwen KA, Seitz HJ. 2003. Regulation of mitochondrial biogenesis by thyroid hormone. *Exp Physiol* 88:121–128.
- Wijayarathne AL, McDonnell DP. 2001. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. *J Biol Chem* 276:35684–35692.
- Wong DJ, Nuyten DSA, Regev A, Lin M, Adler AS, Segal E, van de Vijver MJ, Chang HY. 2008. Revealing targeted therapy for human cancer by gene module maps. *Cancer Res* 68:369–378.
- Yang S-H, Prokai L, Simpkins JW. 2006. Correspondence regarding Schwend and Gustafsson, "False positives in MALDI-TOF detection of ER[beta] in mitochondria". *Biochem Biophys Res Commun* 345:917–918.
- Zhai P, Eurell TE, Cooke PS, Lubahn DB, Gross DR. 2000a. Myocardial ischemia-reperfusion injury in estrogen receptor-alpha knockout and wild-type mice. *Am J Physiol Heart Circ Physiol* 278:H1640–H1647.
- Zhai P, Eurell TE, Cotthaus R, Jeffery EH, Bahr JM, Gross DR. 2000b. Effect of estrogen on global myocardial ischemia-reperfusion injury in female rats. *Am J Physiol Heart Circ Physiol* 279:H2766–H2775.
- Zhao Y, Xu J-X. 2004. The operation of the alternative electron-leak pathways mediated by cytochrome c in mitochondria. *Biochem Biophys Res Commun* 317:980–987.